Ask about this productRelated genes to: PGM1 antibody
- Gene:
- PGM1 NIH gene
- Name:
- phosphoglucomutase 1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 1p31.3
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: PGM1 antibody
Related articles to: PGM1 antibody
- Lung cancer remains a leading cause of cancer incidence and mortality globally. Metabolic reprogramming promotes tumor progression and shapes an immunosuppressive tumor microenvironment. Galactose metabolism is involved in multiple malignancies, but its prognostic value in lung adenocarcinoma (LUAD) remains unclear. This study aimed to develop and internally validate a galactose metabolism-related multigene prognostic model for LUAD. - Source: PubMed
Publication date: 2026/08/27
Zhang FengFu JianCui XuxuGao XutongKang Yanxia - Triple-negative breast cancer (TNBC) is characterized by high metastatic tendency and poor prognosis, largely driven by dynamic crosstalk between cancer cells and the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) are a major component of the TME, yet their functional contributions to TNBC progression remain incompletely understood. In this study, we isolated exosomes from patient-derived CAFs and normal fibroblasts (NFs), and profiled their circRNA content using RNA sequencing. circFAD104 was significantly enriched in CAFs and their derived exosomes, with elevated stromal expression confirmed by qRT-PCR and in situ hybridization (ISH). PKH26 labeling demonstrated that CAF-derived exosomes efficiently deliver circFAD104 to TNBC cells, where it enhances cancer stemness, metastasis, and glycolysis. Mechanistically, circFAD104 acts as a molecular scaffold to promote the interaction between the E3 ubiquitin ligase MARCHF8 and its substrate PGM1, facilitating MARCHF8-mediated K48-linked ubiquitination and subsequent proteasomal degradation of PGM1. Loss of PGM1 redirects glucose flux from glycogen synthesis toward glycolysis, thereby fueling tumor progression. Clinically, high circFAD104 levels were correlated with poorer overall survival in breast cancer patients. These findings uncover a CAF-exosomal circFAD104 axis that reprograms glucose metabolism to drive TNBC progression via the circFAD104/MARCHF8/PGM1 pathway, highlighting its potential as a stroma-targeted biomarker and prognostic predictor. - Source: PubMed
Publication date: 2026/08/29
Wang LeiLi XiaoyanLiang YiranWang YifeiJin YuhanWang JianingLuo DanYang YuxiaYang JingzeLi YamingChen TongHan DianwenWang ZekunZhao WenjingChen BingWang LijuanYang Qifeng - Combining metabolomics and proteomics, this study aimed to investigate the effects of resveratrol (RES) on meat quality, antioxidant capacity, muscle fiber characteristics and mitochondrial function in Tibetan sheep. - Source: PubMed
Publication date: 2026/08/14
Li XiongxiongLu ZengkuiYuan ChaoZheng ChenLiu TingChen BowenWang JingLiu Jianbin - This case report expands the limited literature on phosphoglucomutase-1 deficiency (GSD XIV), a rare disorder that combines features of glycogen storage disease and congenital disorders of glycosylation. Given its wide clinical spectrum and often subtle early signs, under-recognition remains common. We report this case to highlight its multisystem involvement, emphasize diagnostic challenges, and reinforce the need for early consideration of GSD XIV in patients with unexplained hepatic, metabolic, and neuromuscular abnormalities. - Source: PubMed
Publication date: 2026/09/09
Al Dojan Khalid AdelSulaiman Samia AzizAlaarag Abdallah - Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by glycolipid dysregulation and hepatic steatosis. Centella asiatica (CA) and its triterpenoid constituents exert metabolic benefits. In addition, previous metabolomics study found that asiatic acid regulated pyrimidine metabolism in obese mice, while the key target and pathway were undefined. This study investigated the regulatory effects of CA and its active constituents on T2DM-related glycolipid disorders, focusing on the pyrimidine metabolism pathway. T2DM mice were established using a high-fat diet combined with streptozotocin (STZ) and treated with Centella asiatica ethanolic extract or asiatic acid (AA), with glibenclamide as a positive control. Then, glycolipid metabolism, hepatic function, pyrimidine metabolites, and related mechanisms were assessed using biochemical assays, LC-MS/MS, cellular experiments, molecular analyses, and molecular docking. CAE and AA significantly reduced FBG (decreased by 51.01% and 53.01%), improved glucose intolerance, corrected dyslipidemia, alleviated hepatic steatosis, and attenuated insulin resistance in T2DM mice. They elevated hepatic uridine, cytidine, and UDP-glucose (UDPG) levels, promoted glycogen synthesis, inhibited uridine phosphorylase 1 (UPP1) activity, upregulated UDPG synthesis genes (PGM1, UGP2), and downregulated lipogenic genes (ACACA, Fasn, SREBP1/2). Molecular docking indicated specific binding of AA and asiaticoside to UPP1. This work distinguishes from our prior research by identifying UPP1 as a functional target and elucidating the detailed molecular mechanism. CA improves T2DM-associated glycolipid disorders and hepatic injury by modulating the pyrimidine metabolism-UDPG-glycogen synthesis pathway and targeting UPP1, highlighting its therapeutic potential for metabolic diseases. - Source: PubMed
Publication date: 2026/06/27
Shen YunjiaoYao YuanyuanLiu ZhihuiLi YiCao ShijieFeng Xinchi